Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Average Target Price of $110.91 According to Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have received an average rating of “Moderate Buy” from the seventeen brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $110.91.

GPCR has been the topic of several research analyst reports. Wall Street Zen cut Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. HC Wainwright reaffirmed a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, Weiss Ratings lowered shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $27.67 on Friday. Structure Therapeutics has a 1 year low of $25.59 and a 1 year high of $94.90. The company has a market cap of $1.93 billion, a PE ratio of -27.67 and a beta of -1.30. The stock’s 50-day moving average is $44.67 and its 200 day moving average is $45.79.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Analysts expect that Structure Therapeutics will post -1.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. IFP Advisors Inc purchased a new stake in Structure Therapeutics in the second quarter worth $46,000. Squarepoint Ops LLC lifted its position in Structure Therapeutics by 454.5% during the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after buying an additional 102,929 shares during the period. Seven Fleet Capital Management LP lifted its position in Structure Therapeutics by 197.8% during the second quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock valued at $1,442,000 after buying an additional 17,800 shares during the period. Wellington Management Group LLP lifted its position in Structure Therapeutics by 1.6% during the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after buying an additional 119,146 shares during the period. Finally, Handelsbanken Fonder AB bought a new stake in shares of Structure Therapeutics during the 2nd quarter valued at $1,041,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.